NCT01379521View on ClinicalTrials.gov

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

PHASE2TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

everolimus

DRUG

everolimus placebo

Trial Locations (5)

807

Novartis Investigative Site, Kaohsiung City

33305

Novartis Investigative Site, Linkou District

50200

Novartis Investigative Site, Chiang Mai

83301

Novartis Investigative Site, Kaohsiung

Unknown

Novartis Investigative Site, Hong Kong

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY